Pato MT, Pigott TA, Hill JL et al. (1991), Controlled comparison of buspirone and clomipramine in obsessive-compulsive disorder. Am J Psychiatry 148(1):127-129.
Pigott TA, L'Heureux F, Hill LJ et al. (1992), A double-blind study of adjuvant buspirone hydrochloride in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 12(1):11-18.
Pigott TA, Pato MT, L'Heureux F et al. (1991), A controlled comparison of adjuvant lithium carbonate or thyroid hormone in clomipramine-treated patients with obsessive-compulsive disorder. J Clin Psychopharmacol 11(4):242-248.
Saxena S, Wang D, Bystritsky A, Baxter LR Jr (1996), Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J Clin Psychiatry 57(7):303-306 [see comment].
Sevincok L, Topuz A (2003), Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J Clin Psychopharmacol 23(5):448-450.
Sevincok L, Uygur B (2002), Venlafaxine open-label treatment of patients with obsessive-compulsive disorder. Aust N Z J Psychiatry 36(6):817 [letter].
Vallejo J, Olivares J, Marcos T et al. (1992), Clomipramine versus phenelzine in obsessive-compulsive disorder. A controlled clinical trial. Br J Psychiatry 161:665-670.
Weiss EL, Potenza MN, McDougle CJ, Epperson CN (1999), Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry 60(8):524-527.